Details of the Drug Combinations

General Information of This Drug (ID: DM9BPLW)

Drug Name
Grazoprevir   DM9BPLW
Synonyms
Grazoprevir; Grazoprevir [INN]; Grazoprevir anhydrous; MK 5172; MK-5172; MK5172; OBMNJSNZOWALQB-NCQNOWPTSA-N; SCHEMBL2175313; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; 1350514-68-9; 8YE81R1X1J; CHEBI:132975; CHEMBL2063090; DTXSID50159234; EX-A2253; UNII-8YE81R1X1J
Indication
Disease Entry ICD 11 Status REF
Hepatitis C 1E51 Approved [1]
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Grazoprevir + Elbasvir DCPE739 Elbasvir Hepatitis C [2]
Grazoprevir + Elbasvir DCEMB4N Elbasvir Hepatitis C [3]
------------------------------------------------------------------------------------
1 Approved Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Grazoprevir + Elbasvir DCDBNYX Elbasvir HCV-1 and HCV-4 infection [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 ClinicalTrials.gov (NCT01717326) A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
3 ClinicalTrials.gov (NCT02332707) Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
4 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.